BioSight
Companies
CytomX Therapeutics, Inc. logo

CTMX

NASDAQSOUTH SAN FRANCISCO, CA
CytomX Therapeutics, Inc.

CytomX Therapeutics develops drug candidates using its PROBODY conditionally activated platform technology, which is designed to improve the effectiveness and safety of therapeutics. The company is focused on clinical development, with ongoing clinical trials and regulatory submissions underway for multiple product candidates. CytomX also partners with collaborators to develop and commercialize its product candidates.

Price history not yet available for CTMX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar